What causes hyperkalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Hyperkalemia

Hyperkalemia is primarily caused by impaired renal excretion of potassium, medication effects, transcellular shifts, and increased potassium intake, with renal dysfunction being the most significant risk factor. 1

Major Causes of Hyperkalemia

1. Impaired Renal Excretion

  • Renal dysfunction: The most significant risk factor, with patients having eGFR <50 ml/min showing a fivefold increased risk for hyperkalemia when using potassium-influencing medications 2
  • Acute kidney injury (AKI) and chronic kidney disease (CKD): Decreased tubular flow rate in AKI and limitations in adaptive responses in CKD 3
  • Hyporeninemic hypoaldosteronism: Results in diminished circulating aldosterone concentrations 3

2. Medication-Induced Hyperkalemia

Medications can cause hyperkalemia through several mechanisms:

Medications that Inhibit Renin-Angiotensin-Aldosterone System

  • Angiotensin-converting enzyme inhibitors (ACEIs)
  • Angiotensin-II receptor blockers (ARBs)
  • Direct renin inhibitors
  • Aldosterone antagonists (spironolactone, eplerenone)
  • Potassium-sparing diuretics (amiloride, triamterene) 4

Medications that Alter Transmembrane Potassium Movement

  • Beta-blockers
  • Calcium channel blockers
  • Suxamethonium (depolarizing muscle relaxant)
  • Mannitol
  • Amino acids 4

Other Medications

  • NSAIDs (inhibit prostaglandin synthesis and reduce renal blood flow)
  • Calcineurin inhibitors (cyclosporine, tacrolimus)
  • Heparin and derivatives (suppress aldosterone production)
  • Trimethoprim and pentamidine (block distal tubule sodium channels) 4

3. Transcellular Shifts

  • Acidosis: Hydrogen ions move into cells, forcing potassium out
  • Insulin deficiency/hyperglycemia: Reduces cellular potassium uptake
  • Beta-blocker therapy: Blocks cellular potassium uptake
  • Cell lysis conditions: Tumor lysis syndrome, rhabdomyolysis, hemolysis, severe burns 1, 5

4. Increased Potassium Intake

  • Excessive dietary intake (especially in patients with impaired renal function)
  • Potassium supplements
  • Potassium-containing salt substitutes
  • Blood transfusions (particularly stored blood) 1, 4

Risk Factors for Developing Hyperkalemia

  • Decreased renal function: eGFR <50 ml/min is the most significant risk factor 2
  • Heart failure: Up to 40% of patients with chronic heart failure develop hyperkalemia 6
  • Diabetes mellitus: Often associated with hyporeninemic hypoaldosteronism
  • Concomitant use of multiple potassium-influencing medications: Particularly RAAS inhibitors with potassium-sparing diuretics or potassium supplements 2
  • Advanced age: Associated with decreased renal function
  • Volume depletion: Can worsen renal function and paradoxically increase hyperkalemia risk 6

Clinical Implications

  • Hyperkalemia follows a U-shaped mortality curve, with both high and low potassium levels increasing risk 6
  • Potassium levels >5 mmol/L are associated with higher mortality in heart failure patients 6
  • Even upper normal range potassium levels (4.8-5.0 mmol/L) are associated with increased 90-day mortality in heart failure patients 6
  • ECG changes correlate with increasing potassium levels, from peaked T waves at 5.5-6.5 mmol/L to potentially fatal arrhythmias at >10 mmol/L 6

Common Pitfalls and Caveats

  • Laboratory errors: Pseudohyperkalemia can occur due to hemolysis during blood collection, thrombocytosis, or leukocytosis
  • Overlooking medication interactions: Failing to recognize combinations of medications that synergistically increase potassium levels
  • Inadequate monitoring: Not monitoring potassium levels in high-risk patients, especially when starting or adjusting doses of RAAS inhibitors
  • Transcellular shifts: Not considering conditions that cause potassium to shift from intracellular to extracellular space
  • Rebound hyperkalemia: Can occur after treatment if the underlying cause is not addressed

Understanding these causes and risk factors is essential for preventing, identifying, and appropriately managing hyperkalemia in clinical practice.

References

Research

Potassium Disorders: Hypokalemia and Hyperkalemia.

American family physician, 2023

Research

Potassium and renal failure.

Comprehensive therapy, 1981

Research

Drug-induced hyperkalemia.

Drug safety, 2014

Research

Potassium Disorders: Hypokalemia and Hyperkalemia.

American family physician, 2015

Guideline

Cardiac Complications and Potassium Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.